By Dr. Benjamin Caplan, MD | Board-Certified Family Physician, CMO at CED Clinic | Evidence Watch
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →Several randomized controlled trials in children with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex have demonstrated meaningful seizure reductions with purified cannabidiol (Epidiolex). A 2025 narrative review in Indian Pediatrics synthesizes this trial data alongside practical dosing, drug interaction, and safety monitoring guidance for clinicians managing drug-resistant pediatric epilepsy.
CBD in Childhood Epilepsy: What the Evidence Actually Shows
A 2025 clinical review published in Indian Pediatrics summarizes randomized controlled trial data, dosing guidance, drug interaction profiles, and safety monitoring protocols for cannabidiol use in pediatric drug-resistant epilepsy syndromes including Lennox-Gastaut, Dravet, and tuberous sclerosis complex.
#78
Strong Clinical Relevance
Directly addresses FDA-approved cannabidiol use in pediatric epilepsy with actionable dosing and monitoring guidance drawn from multiple RCTs.
Pediatric Epilepsy
Drug-Resistant Seizures
Drug Interactions
Epidiolex
Drug-resistant epilepsy in children remains one of the most consequential challenges in pediatric neurology, with many families exhausting conventional antiseizure medications before achieving adequate seizure control. Cannabidiol (CBD) has emerged as a treatment with regulatory approval for specific severe epilepsy syndromes, yet significant confusion persists among clinicians and families about what the evidence actually supports, how to dose appropriately, and which drug interactions demand vigilance. A concise synthesis of RCT data, dosing protocols, and safety monitoring requirements meets a genuine clinical need, particularly in global settings where access to both the FDA-approved formulation and specialist guidance varies widely.
Cannabidiol exerts anticonvulsant effects through multiple proposed mechanisms, including modulation of GPR55, TRPV1 channels, and adenosine reuptake, distinct from the psychoactive properties of THC. The regulatory landscape shifted substantially when the FDA approved purified CBD (Epidiolex) for Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC) in patients aged one year and older, with EMA approval following for those aged two and above. This 2025 narrative review in Indian Pediatrics consolidates the key evidence from several landmark trials that undergird those approvals and offers practical clinical guidance designed for both specialist and general pediatric audiences.
The cited RCTs demonstrate median monthly seizure reductions of approximately 38 to 49 percent for convulsive seizures in Dravet syndrome and 37 to 44 percent for drop seizures in Lennox-Gastaut syndrome at doses of 10 to 20 mg/kg/day. Responder rates, defined as greater than 50 percent seizure reduction, ranged from roughly 36 to 49 percent across trials. The review emphasizes a clinically critical drug interaction: clobazam co-administration produces a three-fold increase in the active metabolite N-demethylclobazam, substantially raising sedation risk. Hepatotoxicity monitoring with liver function tests at baseline and at one, three, and six months is recommended. The authors acknowledge that evidence for off-label CBD use in other epilepsy syndromes remains limited, and that artisanal CBD products, while showing comparable observational responder rates, lack rigorous trial-level evidence and exhibit substantial content variability.
This review does a commendable job of distilling what are genuinely strong RCTs into a format that working clinicians can use. The trial data for Epidiolex in LGS, DS, and TSC is among the most rigorous evidence anywhere in cannabinoid medicine, and it deserves the clarity this paper provides. That said, the gap between having an approved drug with solid trial data and making it accessible to the families who need it remains wide. Cost is a real barrier, and when families turn to artisanal products as a workaround, the evidence base drops off sharply and the safety profile becomes much harder to predict.
In my practice, when I see families considering cannabidiol for refractory seizures, the conversation always starts with the approved formulation and the importance of coordination with their neurologist. I pay close attention to the clobazam interaction because it is both common and clinically significant. For families who cannot access Epidiolex, I am honest about the limitations of artisanal alternatives and the necessity of independent lab testing, liver monitoring, and close follow-up. This is not an area where we can afford to guess.
This review sits at a useful junction in the research arc: the pivotal RCTs have been completed, regulatory approvals secured, and the clinical community now needs consolidated, actionable guidance on implementation. The evidence for the three approved indications is well-established by the standards of epilepsy therapeutics, with effect sizes that are clinically meaningful though not curative. Seizure freedom remains uncommon, and the responder rates, while encouraging, leave a substantial proportion of patients without major benefit. The next important evidence milestones involve long-term safety data, head-to-head comparisons with newer antiseizure medications, and rigorous trials in epilepsy syndromes beyond LGS, DS, and TSC.
From a pharmacological standpoint, clinicians must approach the clobazam interaction with the same seriousness they would apply to any drug combination that triples active metabolite levels. The sedation risk is not theoretical; it requires proactive dose adjustment and family counseling. The hepatotoxicity signal, while manageable with appropriate monitoring, adds a real laboratory burden that must be factored into care plans. For clinicians prescribing CBD in this population
